

AbbVie Inc. (ABBV)

Healthcare / Drug Manufacturers - General · New York Stock Exchange

Generated: 2026-Oct-18 · Market data through: 2026-10-16

LAST CLOSE \$285.42 2026-10-16	MARKET CAP \$504.4B VOLUME 5.6M	52-WK HIGH \$291.40 52-WK LOW \$190.75	TRAILING PE 80.4 P/S 7.83	GROSS MARGIN 71.5% NET MARGIN 9.8%	ROE -136% ROIC 13%	PIOTROSKI 9/9 ALTMAN Z 2.7	1-YR RETURN +25.8% 5-YR RETURN +459.3%
---	--	---	--	---	---	---	---

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrovelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

SECTOR Healthcare INDUSTRY Drug Manufacturers - General EXCHANGE NYSE MARKET CAP \$504.4B EMPLOYEES 57,000 (SEC-filed) CEO Robert A. Michael
IPO 2013-01-02 COUNTRY US
1 North Waukegan Road, North Chicago, IL 60064-6400 · Tel 847 932 7900 · abbvie.com

1 INSIDERSTREET SCORE

INSIDERSTREET SCORE

67 / 100

Street mean \$299.50 (12 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNAL

ROUTINE SELLING — LOW SIGNAL

\$19M sold / 6 mo, zero open-market buys


2 PRICE AND VOLUME

adjusted close, prod data layer

1 Year vs S&P 500 · ABBV +25.8% · S&P 500 +15.9% · spread +9.9pp



7 Years vs S&P 500 · ABBV +459.3% · S&P 500 +189.9% · spread +269.5pp



Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

3 INSIDERSTREET SCORE

live IS factor model

INSIDERSTREET
SCORE

67

OF 100

Score Breakdown


Profitability	62/100
Growth	76/100
Momentum	91/100
Quality	72/100
Earnings Quality	59/100
Balance Sheet	26/100
Value	32/100
Risk (safety)	50/100
Overall	66.6/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is **not** the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

SYMBOL	IS SCORE
JNJ	64
MRK	49
NVS	65
AZN	71
AMGN	67
LLY	78
ABBV	67

IS Score Trend — quarterly



4 TWO READINGS

business vs price

BUSINESS QUALITY

67 / 100

IS Score 66.6 / 100 · +0.0 from peak of 67

Quarter	Business Quality
23 Q1	45
23 Q2	42
23 Q3	48
23 Q4	38
24 Q1	45
24 Q2	38
24 Q3	42
24 Q4	38
25 Q1	45
25 Q2	42
25 Q3	58
25 Q4	65
26 Q1	67

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTURE

BULLISH

Technical Score 93 / 100 · Power +86 · 22 of 22 indicator votes bullish

Date	Price Structure
07-23	104%
08-13	23%
09-03	104%
09-25	50%
10-16	104%

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 67 and price structure at 93 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

5 WHAT WOULD CHANGE OUR MIND

falsifiable - check us next quarter

TRIGGER	WHERE IT STANDS NOW	WHAT IT WOULD MEAN
IS Score reaches 75 and holds two consecutive quarters	now 66.6	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 56 → 64 → 58 → 67	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 4,196 → now 4,196	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

6 SMART MONEY CONFLUENCE

EDGE · disclosure sources


SITE CONVERGENCE SCORE 3 of 4 top 4% of 29,420 symbols	SOURCES ALIGNED — of 3 independent disclosures	CONGRESS (180D) 1 buys 2026-05-01	INSIDER BUYS (180D) 0 none disclosed
ETF FUNDS (30D) 1820 up / 1601 down net +219 funds	INSTITUTIONS ADDED (13F) 124 managers opening or increasing		

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

7 INSTITUTIONAL OWNERSHIP - 12-QUARTER TREND

13F · filed 45 days after quarter end

Institutions holding — 12 quarters



Peak 4,196 · latest 4,196 (+0 from peak).

QUARTER	HOLDERS	13F SHARES	VALUE	REPORTED OWN%
2026 Q2	4,196	1342.6M	\$329.3B	75.8%
2026 Q1	4,072	1297.3M	\$275.3B	73.2%
2025 Q4	4,118	1313.7M	\$294.4B	74.2%
2025 Q3	3,858	1266.5M	\$287.6B	71.5%
2025 Q2	3,734	1288.6M	\$234.3B	72.8%
2025 Q1	3,767	1283.0M	\$265.2B	72.5%
2024 Q4	3,694	1272.3M	\$222.6B	71.8%
2024 Q3	3,442	1265.0M	\$244.4B	71.4%
2024 Q2	3,311	1260.1M	\$211.7B	71.2%
2024 Q1	3,323	1250.8M	\$222.7B	70.6%
2023 Q4	3,267	1235.6M	\$188.3B	69.8%
2023 Q3	3,050	1222.3M	\$179.0B	69.0%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY


8 INSIDER ACTIVITY live Form 4 data

INSIDER	ROLE	DATE	TYPE	SHARES	VALUE	POST-TXN OWNED
Quaggin Susan E	director	2026-09-30	A-Award	59	\$0.02M	918
Rapp Edward J	director	2026-09-30	A-Award	129	\$0.03M	29,568
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	2026-08-14	EXERCISE	32,710	\$2.58M	107,140
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	2026-08-14	SELL	32,710	\$8.18M	74,430
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	2026-08-14	EXERCISE	32,710	\$2.58M	0
Rapp Edward J	director	2026-06-30	A-Award	134	\$0.03M	29,236
Quaggin Susan E	director	2026-06-30	A-Award	62	\$0.02M	853
Falk Thomas J	director	2026-05-08	A-Award	1,118	—	2,321

9 SELL DECOMPOSITION — ROUTINE VS. DISCRETIONARY EDGE

6-MO DECOMPOSITION (FORM 4)	TXNS	SHARES	VALUE	SIGNAL WEIGHT
S — Open-market sales	6	78,989	\$18.9M	Counted
M — Exercises (paired A/D)	4	55,091	\$6.4M	None — mechanics
F — Tax withholding	10	140,437	\$32.6M	None — compensation
P — Open-market purchases	0	0	\$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)



Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SIGNAL	OPEN-MARKET SELLS	OPEN-MARKET BUYS	CLUSTER
Routine Selling — Low Signal	\$18.9M 6 txns / 6 mo	\$0.0M 0 txns / 6 mo	None active 3+ insiders / 21 days

10 FORM 144 PLANNED-SALE PIPELINE live EDGAR data

FILED	FILER	SHARES REGISTERED	EST. PROCEEDS
2026-08-14	Nicholas Donoghoe	32,710	\$8.2M
2026-05-26	Robert J Alpern	13,000	\$2.8M
2026-03-06	David R. Purdue	5,230	\$1.2M
2026-03-02	Perry C Siatis	18,668	\$4.4M
Trailing 12 mo	5 filings	91,989	\$22M

11 13D / 13G STAKES COND

FILED	FORM	REPORTING PERSON	% OF CLASS	SHARES
2026-03-26	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2025-07-07	SCHEDULE 13G/A	The Vanguard Group	10.03%	177.3M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

12 CONGRESSIONAL TRADING					EDGE · STOCK Act
MEMBER	CHAMBER	TRADE	SIZE BAND	TRADED	DISCLOSED
Pete Sessions	House	SELL	\$15,001 - \$50,000	2026-09-14	2026-09-21
Ro Khanna	House	SELL	\$15,001 - \$50,000	2026-09-04	2026-10-09
Josh Gottheimer	House	SELL	\$1,001 - \$15,000	2026-05-05	2026-06-04
John Boozman	Senate	SELL	\$1,001 - \$15,000	2025-08-22	2025-09-13
John Boozman	Senate	SELL	\$1,001 - \$15,000	2025-08-22	2025-09-12
John Boozman	Senate	SELL	\$1,001 - \$15,000	2025-08-22	2025-09-12
HOUSE 12-MO 22 trades 3 purchases		SENATE 12-MO 0 trades None purchases		COVERAGE STOCK Act filings 30-45 day disclosure lag	

13

INSTITUTIONAL OWNERSHIP & 13F FLOW

live 13F data

13F FILERS (LAST COMPLETE Q) 4,072	13F SHARES 1.30B 73.2% of shares out	NEW / CLOSED 206 / 180 positions, QoQ	INCREASED / REDUCED 1,722 / 1,685 positions, QoQ
PUT/CALL (13F) 0.98 option positions	FREE FLOAT 99.8% 1.76B sh		

2.8 · Largest Reporting 13F Managers


MANAGER	SHARES	VALUE
Assenagon Asset Management S.A.	1.7M	\$443M
Wealth Enhancement Advisory Servic	763,184	\$180M
Hamlin Capital Management, Llc	728,805	\$191M
Ferguson Wellman Capital Managemen	658,136	\$172M
Mn Services Vermogensbeheer B.V.	522,459	\$137M
Fjarde Ap - Fonden /Fourth Swedish N	513,338	\$134M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.


2.9 · Top ETF & Fund Ownership

FUND	WEIGHT	POSITION
VITSX	0.6%	\$14.7B
VTSAX	0.6%	\$14.7B
VSMPX	0.6%	\$14.7B
VTI	0.6%	\$14.7B
VFFSX	0.7%	\$12.1B
VFIAX	0.7%	\$12.1B

13F Filers Holding ABBV — quarterly



Institutional Put/Call — quarterly




THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

14 SHORT VOLUME — DAILY, 60 SESSIONS

EDGE · live FINRA feed




Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

LATEST SESSION 39.5% 2026-10-15	20-DAY AVG 48.0% 50-day 50.3%	TREND Falling 20d vs 50d	BY MARKET CENTER Q: 39% · N: 40% · B: 46% latest session
--	--	---------------------------------------	---

15 DARK POOL ACTIVITY

EDGE · live ATS data




Where ABBV Trades in the Dark

ATS VENUE (4-WK)	SHARES	AVG TRADE
Incr Intelligent Cross Llc	6.5M	56 sh
Ubsa Ubs Ats	5.5M	60 sh
Ebxl Level Ats	3.8M	42 sh
Sgmt Sigma X2	3.8M	56 sh
Mspl Ms Pool (Ats-4)	3.3M	170 sh
Pure Purestream	2.8M	62 sh

16 REVENUE FLOW — FY2025

live segmentation + income data



Where a dollar of AbbVie Inc. revenue goes. All values FY2025 filings, live.

17 GEOGRAPHIC REVENUE

live segmentation

REGION	REVENUE	SHARE
UNITED STATES	\$46.6B	95%
Non-US	\$2.4B	5%


THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

18 MOAT & COMPETITIVE POSITION

LIVE MODEL · 61/100 NARROW

Moat score 61/100 — Narrow; primary source Efficient Scale.




■ ABBV (live moat model)

■ Peer median: JNJ · MRK · NVS · AZN · AMGN

Component scores from the live moat model. Peer median illustrative.

3.8 · Employees (SEC filings)





19 CORPORATE INFORMATION — KEY OFFICERS

57,000 employees

OFFICER	TITLE
Robert A. Michael	Chief Executive Officer & Chairman of the Board
Jeffrey Ryan Stewart	Executive Vice President & Chief Commercial Officer
Azita Saleki	Executive Vice President & Chief Operating Officer
Scott T. Reents	Executive Vice President & Chief Financial Officer

20 REVENUE & EPS — HISTORY AND ESTIMATES

live consensus




Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

21 ESTIMATE VS. ACTUAL & SURPRISES

live data



22 REPORTED VS. CONSENSUS — FULL HISTORY

0 quarters · live data


BEAT RATE —% 0 of 0 quarters	CURRENT STREAK 0 longest 0	AVG EPS SURPRISE —% median —%	SURPRISE TREND — last 4 vs prior 4
------------------------------------	----------------------------------	-------------------------------------	--

PERIOD	EPS EST.	EPS ACTUAL	EPS SURPRISE	REV EST. (\$M)	REV ACTUAL (\$M)	REV SURPRISE
--------	----------	------------	--------------	----------------	------------------	--------------

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.


INCOME TRENDS — 5 YEAR

live financials



NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked



Live segmentation data.

YoY Growth Heatmap — Income Lines

YOY GROWTH	FY21	FY22	FY23	FY24	FY25
Revenue	+22.7%	+3.3%	-6.4%	+3.7%	+8.6%
Gross profit	+27.4%	+4.9%	-16.6%	+16.3%	+29.8%
Operating income	+57.7%	+1.1%	-29.6%	-28.4%	+132.2%
Net income	+150.0%	+2.5%	-58.9%	-12.0%	-1.2%


23 INCOME STATEMENT — FULL

live financials

\$B · FY ENDS	FY21	FY22	FY23	FY24	FY25	TREND
Revenue	56.2	58.1	54.3	56.3	61.2	
Cost of revenue	17.4	17.4	20.4	16.9	10.0	
Gross profit	38.8	40.6	33.9	39.4	51.2	
R&D expense	8.0	6.5	7.7	12.8	9.1	
SG&A expense	12.3	15.3	12.9	13.2	14.0	
Operating income	17.9	18.1	12.8	9.1	21.2	
EBITDA	23.9	24.2	17.2	14.9	28.3	
D&A	8.5	8.5	8.7	8.4	19.1	
Pretax income	13.0	13.5	6.2	3.7	6.6	
Income tax	1.4	1.6	1.4	-0.6	2.4	
Net income	11.5	11.8	4.9	4.3	4.2	
Diluted EPS (\$)	6.45	6.63	2.72	2.39	2.36	
Diluted shares (M)	1,777	1,778	1,773	1,773	1,791	

CASH FLOW TRENDS


live data



NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

WHERE THE CASH WENT — FY2025

cash Sankey, live data



Balance Sheet — Full



\$B	FY22	FY23	FY24	FY25	
Cash & equivalents	9.2	12.8	5.5	5.2	
ST investments	0.0	0.0	0.0	0.0	
Receivables (net)	11.3	11.2	10.9	12.6	
Total current assets	28.5	33.0	25.6	29.1	
PP&E (net)	4.9	5.0	5.1	6.4	
Goodwill + intangibles	99.6	87.9	95.0	88.3	
Total assets	138.8	134.7	135.2	134.0	
Accounts payable	2.9	3.7	2.9	3.6	
Short-term debt	4.3	7.2	6.8	8.7	
Deferred revenue	0.0	0.0	0.0	0.0	
Total current liabilities	29.5	37.8	38.7	43.3	
Long-term debt	59.1	52.2	60.3	59.6	
Total liabilities	121.5	124.3	131.8	137.2	
Shareholders' equity	17.3	10.4	3.4	-3.2	

Cash Flow Statement — Full

\$B	FY22	FY23	FY24	FY25	
Net income	11.8	4.8	4.3	4.2	
D&A	8.5	8.7	8.4	8.1	
Stock-based compensation	0.7	0.7	0.9	1.0	
Working capital change	(0.3)	2.8	(2.8)	(2.4)	
Operating cash flow	24.9	22.8	18.8	19.0	
Capital expenditures	(0.7)	(0.8)	(1.0)	(1.2)	
Investing cash flow	(0.6)	(2.0)	(20.8)	(6.6)	
Buybacks	(1.5)	(2.0)	(1.7)	(1.0)	
Dividends paid	(10.0)	(10.5)	(11.0)	(11.7)	
Debt issuance / (repay)	(12.4)	(4.1)	7.4	(0.3)	
Financing cash flow	(24.8)	(17.2)	(5.2)	(12.7)	
Free cash flow	24.2	22.1	17.8	17.8	

THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY



Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

24 EXPANDED RATIO ANALYSIS (I)

live ratio engine · profitability · valuation

RATIO	FY21	FY22	FY23	FY24	FY25	TTM	TREND
PROFITABILITY							
ROE	81.0%	72.5%	35.2%	62.5%	15389.1%	-136%	
ROA	7.8%	8.3%	3.6%	3.2%	3.1%	4.7%	
ROIC	19.2%	22.0%	17.2%	16.1%	18.3%	13.5%	
Gross margin	69.0%	70.0%	62.4%	70.0%	83.7%	71.5%	
Operating margin	31.9%	31.2%	23.5%	16.2%	34.7%	29.3%	
Net margin	20.5%	20.4%	9.0%	7.6%	6.9%	9.8%	
EBITDA margin	42.6%	41.6%	31.6%	26.5%	46.3%	32.9%	
FCF margin	39.1%	41.8%	40.6%	31.7%	30.6%	—	
VALUATION							
P/E	17.99	21.75	52.64	71.16	95.78	80.4	
P/B	13.47	14.92	24.71	91.56	-123.96	-85.2	
P/S	3.69	4.43	4.71	5.40	6.63	7.83	
P/FCF	9.44	10.62	11.60	17.07	21.67	27.7	
EV/EBITDA	11.50	12.92	17.66	24.59	26.61	26.8	
EV/Revenue	4.90	5.38	5.58	6.51	7.67	8.8	
Earnings yield	5.6%	4.6%	1.9%	1.4%	1.0%	1.25%	
FCF yield	10.6%	9.4%	8.6%	5.9%	4.6%	3.61%	

EXPANDED RATIO ANALYSIS (II)

leverage · solvency

RATIO	FY21	FY22	FY23	FY24	FY25	TTM	TREND
LEVERAGE & SOLVENCY							
Current ratio	0.79	0.96	0.87	0.66	0.67	0.81	
Quick ratio	0.70	0.84	0.76	0.55	0.56	0.69	
Debt / equity	5.03	3.72	5.80	20.40	-21.12	-11.93	
Debt / assets	52.9%	46.2%	44.6%	50.2%	51.6%	52.4%	
Net debt / EBITDA	2.83	2.27	2.75	4.18	3.62	3.03	
Interest coverage	6.36	7.04	3.81	2.32	3.28	—	

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

EXPANDED RATIO ANALYSIS (III)							efficiency · growth · per-share · scores
RATIO	FY21	FY22	FY23	FY24	FY25	TTM	TREND
EFFICIENCY							
Asset turnover	0.38	0.41	0.40	0.42	0.45	0.48	
Receivables turnover	5.98	5.47	4.85	5.10	5.20	4.7	
DSO (days)	61	67	75	72	70	78	
DPO (days)	54	61	59	72	73	659	
Cash conversion cycle	74	76	85	89	99	-479	
GROWTH (YoY)							
Revenue growth	22.7%	3.3%	-6.4%	3.7%	8.6%	—	
Net income growth	150.0%	2.5%	-58.9%	-12.0%	-1.1%	—	
EPS growth	150.5%	2.5%	-58.8%	-12.1%	-1.1%	—	
FCF growth	31.0%	10.3%	-9.0%	-19.2%	4.9%	—	
PER SHARE (\$)							
EPS (diluted, TTM)	6.49	6.66	2.74	2.41	2.39	3.57	
Book value / share	8.67	9.70	5.85	1.88	-1.84	-3.31	
Revenue / share	31.61	32.65	30.65	31.77	34.48	36.36	
FCF / share	12.37	13.64	12.45	10.06	10.54	10.28	
Cash / share	5.53	5.19	7.23	3.13	2.96	3.71	
SHAREHOLDER RETURN & SCORES							
Buyback yield	0.4%	0.6%	0.8%	0.6%	0.2%	0.34%	
Altman Z-Score	1.65	2.10	1.79	1.76	2.17	2.7	
Piotroski F-Score	8	9	5	5	6	9/9	
Beneish M-Score	-2.77	-2.85	-3.03	-3.02	-2.94	-2.82	

25 EARNINGS QUALITY PANEL				live scores
MODEL	SCORE	ZONE	NOTE	
Piotroski F-Score	9 / 9	Strong		
Altman Z-Score	2.7	Grey zone	Grey	
Income quality	3.09	Cash-backed	OCF ÷ net income	
Beneish M-Score	-2.82	Non-manipulator	vs -2.22 threshold	

26 DUPONT & GROWTH QUALITY				live analysis engine
DUPONT DECOMPOSITION (TTM)		VALUE	GROWTH QUALITY (LIVE)	VALUE
Tax burden		0.73	Revenue stability	0.72
Interest burden		0.65	Earnings stability	0.30
Operating margin		20.7%	Earnings persistence	0.50
Asset turnover		0.47×	Revenue CAGR 3y	4.7%
Financial leverage		-44.51×	EPS CAGR 3y	-10.1%
= ROE		-206%	FCF CAGR 3y	-8.3%


THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

SHAREHOLDER RETURN PROFILE live

BUYBACK YIELD 0.34%	DIVIDEND YIELD 2.42%	TOTAL SHAREHOLDER RETURN 2.84% cash yield	SBC / REVENUE 1.5% dilution pressure
-------------------------------	--------------------------------	--	---

27 MULTIPLE HISTORY — FY SNAPSHOTS + TTM live ratio engine



28 PEER COMPARISON live peer engine

COMPANY	MKT CAP	P/E	ROE	NET MARGIN	REV GROWTH	PIOTROSKI	1-YR RET
JNJ	\$615.9B	38.7	26%	21.9%	+8.1%	7/9	+33.9%
MRK	\$360.1B	115.8	7%	-8.0%	+4.5%	4/9	+75.4%
NVS	\$286.3B	22.9	31%	22.7%	+0.8%	5/9	+15.1%
AZN	\$256.5B	24.7	22%	16.3%	+8.6%	9/9	-1.5%
AMGN	\$233.8B	26.7	91%	23.6%	+9.2%	8/9	—
LLY	\$1,183.3B	42.1	102%	30.9%	+49.6%	9/9	—
GILD	\$193.7B	-60.1	-21%	—	+5.5%	5/9	—
PFE	\$168.6B	39.1	5%	-1.6%	-0.2%	7/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

29 ANALYST CONSENSUS & ESTIMATES live consensus

Buy

44 Analysts



MEAN TARGET (QTR) \$299.50 12 targets	TARGET VS. PRICE +4.9% last-quarter mean	NEXT REPORT 2026-10-30 street \$3.74
--	---	---

CONSENSUS ESTIMATES	REVENUE MEAN	HIGH / LOW	EPS MEAN	HIGH / LOW	# EPS EST.
FY2026	\$67.63B	\$67.98B / \$67.49B	\$13.95	\$14.23 / \$13.79	15
FY2027	\$73.50B	\$74.87B / \$71.86B	\$16.38	\$17.37 / \$15.52	14
FY2028	\$79.00B	\$81.64B / \$75.17B	\$17.88	\$20.89 / \$15.47	8

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

30 STREET TARGETS & THIRD-PARTY RATING

live targets + composite

Street Price Target — Trajectory

WINDOW	AVG TARGET	VS. PRICE	# TARGETS
Last Month	\$306.67	+7.4%	3
Last Quarter	\$299.50	+4.9%	12
Last Year	\$275.07	-3.6%	42
All Time	\$222.76	-22.0%	98

Rolling mean of published targets vs. last close \$285.42. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

C

DCF

3/5

ROE

1/5

ROA

4/5

DEBT/EQ

1/5

P/E

1/5

P/B


1/5

Independent quant composite as of 2026-10-16; components scored 1-5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

31 PRICE PERFORMANCE — INDEXED, 12 MO

live prices · benchmark + sector + peer set

ABBV +25.8% vs S&P 500 +15.9% — spread +9.9pp



All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL CHART — 6-MONTH DAILY CANDLES, INDICATORS ON

site chart, print edition



Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

MOVING AVERAGE RIBBON & TREND

site technicals-tab chart, live indicator history



MOVING AVERAGE	VALUE	DISTANCE	% DISTANCE	SIGNAL
SMA 20	\$269.02	+16.40	+6.10%	Above
SMA 50	\$262.09	+23.33	+8.90%	Above
SMA 200	\$233.59	+51.83	+22.19%	Above
EMA 9	\$276.93	+8.49	+3.07%	Above
EMA 21	\$270.65	+14.77	+5.46%	Above
EMA 50	\$262.79	+22.63	+8.61%	Above
EMA 200	\$239.31	+46.11	+19.27%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

32 TECHNICAL POWER SCORE

EDGE · site engine · 93/100 composite

TECHNICAL VERDICT

BULLISH

Power Score +86

22 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%

Momentum 25%

Volume 20%

Volatility 10%

Patterns 15%

100

100


94

100

62

BULLISH — BUT WHICH WAY IS IT TRENDING?

vote share recomputed weekly, 13 weeks




INDICATOR VOTE GRID

22 bull / 0 bear

● Price vs SMA 20	\$269.02	● Price vs SMA 50	\$262.09	● Price vs SMA 200	\$233.59
● EMA 9/21 Cross	276.9/270.6	● SMA 50/200	Golden	● ADX Direction	ADX 28
● Supertrend	\$266	● Parabolic SAR	\$267	● SMA Slope	1.070
● RSI	71.1	● Stochastic K/D	84/83	● StochRSI K/D	87/80
● Williams %R	-17	● CCI	167	● TSI vs Signal	31.1
● CMO	42.2	● ROC	9.26%	● OBV Signal	Accum
● Chaikin MF	0.100	● MFI	61	● Force Index	10M
● Elder Ray Bull	15.99				

INDICATOR GAUGES

site technicals-tab style



33 KEY LEVELS & VOLATILITY

live indicator table

LEVEL	VALUE	LEVEL	VALUE
Pivot / R1 / R2	\$285.87 / \$288.93 / \$294.46	S1 / S2	\$280.34 / \$277.28
Bollinger (20,2)	\$253.40 - \$284.64	Squeeze	Off
52-wk range	\$190.75 - \$291.40	Off 52-wk high	-2.0%
ATR (14)	\$6.46 (2.3%)	Historical vol	19.7%


NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

34 SEASONALITY — 14-YEAR AVERAGES										live model · win rates shown	
-1.1%	+3.3%	-0.8%	+2.6%	-0.4%	+1.4%	+1.4%	+0.3%	+2.3%	+1.0%	+4.9%	+2.9%
Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
36%	71%	57%	62%	31%	62%	62%	46%	54%	62%	69%	69%

Sample: 14 years — treat short histories as suggestive, not statistical.

35 RISK INDICATORS			computed from live price history	
COMPUTED FROM LIVE WEEKLY PRICES		ABBV	S&P 500	
Weekly volatility (σ , 1y)		3.32%	1.83%	
Best / worst week (1y)		+6.9% / -8.5%	—	
Max drawdown (5y, monthly)		-27.0%	—	
1-week VaR (95%)		-5.4%	—	
Beta (5y)		0.28	1.00	

36 EQUITY WEATHER & MARKET REGIME		EDGE · live weather engine	
ABBV EQUITY WEATHER (LIVE)		MARKET REGIME (2026-10-16)	
PARTLY CLOUDY · +30		NEUTRAL	
Trend	+51	VIX	19.99
Momentum	+65	Normal	
Volume	+51	DOW THEORY	Confirmed Bearish
Volatility	-60	SPY / QQQ TSI	7.2 / 4.7
Breadth	-30	trend strength	
		SECTOR STRENGTH	46/100
		breadth average	



THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

38 WEATHER - COMPANY VS INDUSTRY, SECTOR, UNIVERSE

EDGE · live weather engine · Partly Cloudy

OVERALL +29.6 +39.1 vs industry	TREND +50.5 +54.6 vs industry	MOMENTUM +65.3 +55.4 vs industry	VOLUME +50.8 +34.2 vs industry
--	--	---	---

READING	ABBV	DRUG MANUFACTURERS - GENERAL N=150	HEALTHCARE N=5,272	ALL US SYMBOLS N=70,435
Overall	+29.6	-9.5	-24.0	-20.5
Trend	+50.5	-4.1	-25.6	-21.3
Momentum	+65.3	+9.9	-28.5	-15.8
Volume	+50.8	+16.6	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

39 EXECUTIVE COMPENSATION


live proxy data · FY2025

EXECUTIVE	TOTAL COMP	STRUCTURE
Robert A. Michael Chairman of the Board and	\$32.5M	57% equity+incentive
Jeffrey R. Stewart Executive Vice President,	\$15.4M	54% equity+incentive
Scott T. Reents Executive Vice President, Ch	\$12.4M	54% equity+incentive
Azita Saleki-Gerhardt Executive Vice Preside	\$10.8M	57% equity+incentive
Roopal B. Thakkar Executive Vice President,	\$9.9M	64% equity+incentive

40 ESG ASSESSMENT

live disclosure-derived scores

PILLAR (LIVE DISCLOSURE SCORES)	SCORE
Environmental	63
Social	62
Governance	69
Composite ESG	65



41 8-K MATERIAL EVENTS

live EDGAR feed

FILED	8-K CONTENTS	ITEMS
2026-10-15	Officer/Director Change	5.02
2026-10-05	Earnings Release; Exhibits	2.02,9.01
2026-09-03	Regulation FD; Exhibits	7.01,9.01
2026-08-18	Other Events; Exhibits	8.01,9.01
2026-08-05	Other Events; Exhibits	8.01,9.01
2026-07-31	Earnings Release; Exhibits	2.02,9.01
2026-07-06	Earnings Release; Exhibits	2.02,9.01
2026-06-22	Regulation FD; Exhibits	7.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

42 METHODOLOGY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

43 DISCLOSURES

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

44 DATA PROVENANCE FOR THIS REPORT

[sources](#) · [coverage](#) · [method](#)

DATA DOMAIN	SOURCE	COVERAGE FOR THIS REPORT
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-30 to 2026-07-31
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	63 rows · 1987 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-05-08 to 2026-09-30
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	2 rows · 2025-07-07 to 2026-03-26
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.